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had been continuously infused with siRNA for 7 days. In ad-
dition, a significant upregulation of  p -p44/42 MAPK (ERK1/2; 
Thr202/Tyr204) and  p -CREB (Ser133) in striatal neurons was 
found. These results suggest that application of the gene si-
lencing targeting NR2B could be a potential treatment of PD, 
and they also revealed the possibility of NR2B-specific siRNA 
being involved in the prosurvival pathway. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Glutamate is the major excitatory neurotransmitter in 
the basal ganglia  [1–3] . Overactivation of the indirect 
pathway, which includes the glutamatergic transmission 
from the cortex to the striatum and from the subthalam-
ic nucleus to the output nuclei of the circuit  [4–6] , is 
thought contribute to the development of some of the 
symptoms of Parkinson’s disease (PD)  [7] . In the stria-
tum, N-methyl- D -aspartic receptors (NMDARs) are 
ionotropic glutamate receptors which are mostly found to 
be expressed in the subpopulations of striatal neurons, 
including striatal projection neurons, i.e. the medium 
spiny neurons  [8–11] . The NMDAR 2B (NR2B) subunit is 
reported to be the dominant NR2 subunit in the striatum 
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 Abstract 
 In the present study, N-methyl- D -aspartate receptor 2B 
(NR2B)-specific siRNA was applied in parkinsonian models. 
Our previous results showed that reduction in expression of 
N-methyl- D -aspartate receptor 1 (NR1), the key subunit of N-
methyl- D -aspartate receptors, by antisense oligos amelio-
rated the motor symptoms in the 6-hydroxydopamine 
(6-OHDA)-lesioned rat, an animal model of Parkinson’s dis-
ease (PD) [Lai et al.: Neurochem Int 2004; 45: 11–22]. To further 
the investigation on the efficacy of gene silencing, small in-
terference RNA (siRNA) specific for the NR2B subunit was de-
signed and administered in the striatum of 6-OHDA-lesioned 
rats. The present results show that administration of NR2B-
specific siRNA decreased the number of apomorphine-in-
duced rotations in the lesioned rats and that there was a sig-
nificant reduction in NR2B proteins levels after NR2B-specif-
ic siRNA administration. Furthermore, attenuation of the loss 
of dopaminergic neurons was found in both the striatal and 
substantia nigra regions of the 6-OHDA-lesioned rats that 
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 [12, 13] . Previous studies in our laboratory suggested the 
reduction in expression of NMDAR 1 (NR1), the key sub-
unit of NMDARs, by employing antisense oligonucle-
otides could ameliorate the motor symptoms in the 6-hy-
droxydopamine (6-OHDA)-lesioned rat, which is an ani-
mal model of PD  [14] . Furthermore, Sze et al. [15] showed 
that a single dose of NR2B-specific antisense oligodeoxy-
nucleotide could successfully block the gene expression 
of NR2B in neurons of the striatum. Blocking the gene 
expression of NR2B is therefore found to have potential 
to generate antiparkinsonian effects. 
 On the one hand, activation of NMDARs contributes 
to either neuroprotective  [16–19] or neurodestructive 
 [20–23] effects, depending on the subcellular localization 
of the receptors, as the activation of synaptic NMDARs 
promotes cell survival signaling pathways, whereas acti-
vation of extrasynaptic NMDARs promotes cell death 
signaling pathways  [23] . Moreover, NR2A- and NR2B-
containing NMDARs are suggested to be expressed in 
both synaptic and extrasynaptic sites with different ratios 
 [24, 25] . In the synaptic region, NR2A-containing 
NMDARs are predominant and can be expressed in ei-
ther a diheteromeric form with NR1 (NR1/NR2A) or tri-
heteromeric form with NR1 and NR2B (NR1/NR2A/
NR2B)  [25–27] . On the other hand, the NR1/NR2B dihet-
eromer NMDARs are predominant in the extrasynaptic 
region  [24, 25, 28, 29] . This suggests that NR2A-contain-
ing NMDARs contribute to the cell survival signaling 
pathway while NR1/NR2B-containing NMDARs con-
tribute to the cell death pathway  [25] . The mechanisms of 
the two subpopulations of NMDARs exerting opposite 
effects are still under investigation. The differences in 
functions between the synaptic and extrasynaptic 
NMDARs were related to the different proteins incorpo-
rated with the cytoplasmic C-terminal of each NR2 sub-
unit, which leads to the activation of different postsynap-
tic signaling pathways  [25, 30, 31] . One of the well-known 
signaling pathways interacting with NMDAR is the ex-
tracellular signal-regulated kinase 1/2 (ERK1/2) signal-
ing pathway. Activation of the ERK1/2 signaling pathway 
was reported to cause the phosphorylation of a number 
of substrates such as transcription factors, signaling mol-
ecules and apoptosis-related proteins  [32, 33] .
 In the present study, small interference RNA (siRNA) 
specific for NR2B were employed as molecular tools for 
investigating the gene expression and functions of 
NMDARs in striatal neurons. By comparing it with the 
traditional antisense oligonucleotide gene knockdown 
strategy, RNAi-mediated gene silencing was suggested to 
have a higher efficiency  [34] . 
 The objectives of the present study were to investigate 
the effects of NR2B-specific siRNA on the behavioral 
symptoms and on the striatal and substantia nigra (SN) 
neurons in the animal model of PD. Moreover, the ac-
tivities of the signaling pathways and the mechanisms of 
the neuroprotective effects after application of NR2B-
specific siRNA in an animal model of PD were also in-
vestigated. Our experiments focused on the ERK1/2
signaling pathway, the change of the protein levels of 
phosphorylated-RAF proto-oncogene serine/threonine-
protein kinase  ( p -c-Raf), phosphorylated-MEK ( p -
MEK1/2), phosphorylated-p44/42 MAPK (also known
as extracellular signal-regulated kinases, ERK1/2;  p -
ERK1/2; Thr202/Tyr204) and phosphorylated-cAMP re-
sponse element-binding  ( p -CREB), which were reported 
to be the downstream of the activation of the NMDAR-
dependent signaling pathway. We investigated their ef-
fect on the animal models continuously infused with 
NR2B-specific siRNA.
 Animals and Methods 
 Animals 
 A total of 153 male Sprague-Dawley rats weighing 200–250 g 
were used. The animals were obtained from the Laboratory Ani-
mal Unit of the University of Hong Kong. The handling of rats 
and all procedures involving in the use of animals in the experi-
ments were approved in accordance with the Animals (Control of 
Experiments) Ordinance, Hong Kong Department of Health, 
Hong Kong, SAR. Great efforts were made to minimize the num-
ber of the animals used and reduce the suffering of the animals.
 Unilateral Striatal 6-OHDA Lesions 
 Rats were deeply anesthetized with sodium pentobarbital (20 
mg/kg i.p., Nembutal; Abbott Laboratories) immediately before 
the lesions. The rats were subjected to unilateral stereotaxic injec-
tions of 6-OHDA (Sigma) in two striatal sites by using a 10-  l 
Hamilton syringe at the following stereotaxic coordinates; site (1) 
AP: +1.4 mm, L: –2.6 mm, DV: –5.0 mm; and site (2) AP: –0.4 mm, 
L: –3.8 mm, DV: –5.0 mm. Six microliters of 3 mg/ml in 0.9% sa-
line containing 0.2 mg/ml ascorbic acid 6-OHDA was injected. 
The rate of injection was 1   l/min, and the syringe was left in situ 
for a further 5 min to prevent back-filling along the injection 
tract. The animals were allowed to recover after surgery and kept 
in the animal house of Hong Kong Baptist University.
 Behavioral Screening of 6-OHDA-Lesioned Rats 
 Rat rotation tests were performed in order to determine the 
success of nigrostriatal denervation after 7 days of lesions by in-
jecting apomorphine (1 mg/ml i.p.; Sigma). The number of rota-
tions of each rat in a 30-min test were recorded. Rats turning more 
than 13 anticlockwise rotations in 5-min intervals were regarded 
as successfully lesioned animals.
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 Pharmacological Treatment in the Striatal-Lesioned Rats 
 The nucleotide sequence of NR2B was from the National Cen-
ter for Biotechnology Information (NCBI) sequence database. 
The sequences of the siRNA specific for NR2B (antisense: 5  -
UUGGUACACAU UGCUGUCCAA-3  , sense: 5  -GGACAG CA-
A UGUGUACCAAAA-3  ; homologous to 2985–3303 bp of com-
plete coding sequence of  Rattus norvegicus NMDAR subtype 2B 
mRNA) was manufactured by Dharmacon.
 The pharmacological treatment in the animal models was per-
formed 7 days after lesion surgery. Rats were anesthetized with 
sodium pentobarbital (20 mg/kg i.p., Nembutal; Abbott Labora-
tories). NR2B-specific siRNA (200 n M ) in diethylpyrocarbonate-
treated 0.9% saline was mixed with RNAi vehicle, SilentFect (Bio-
Rad). In single injection models, the rats received stereotaxic in-
jections of 7.8 ng siRNA (Dharmacon) into the striatal region 
using a 10-  l Hamilton syringe with a blunt 33-gauge needle at 
the following stereotaxic coordinates, AP: +0.02 mm, L: –0.32 
mm, DV: –5.0 mm. The injection was administered at a rate of 0.3 
  l/min, and the syringe was left in situ for a further 5 min to pre-
vent back-filling along the injection tract. Moreover, the same 
amount of non-sense siRNA (Dharmacon) was also injected into 
separate animal models as a negative control of the experiment. 
 In the continuous infusion models, NR2B-specific siRNA
(3 n M ) in diethylpyrocarbonate-treated 0.9% saline was mixed 
with RNAi vehicle, SilentFect (Bio-Rad). The osmotic minipumps 
were filled with 7.8 ng of siRNA for infusion at a rate of 24   l/day 
for 1 week (Alzet Model 2001; Durect, Cupertino, Calif., USA). 
The osmotic minipumps were loaded at room temperature, and 
these prefilled pumps were placed in isotonic saline overnight at 
37   °   C before implantation to ensure a steady pumping rate. A 
brain-infusion cannula (Brain Infusion Kit 2, Alzet) was stereo-
taxically placed for infusion from the implanted minipump to the 
striatal region (AP: +0.02 mm, L: –0.32 mm, DV: –5.0 mm). The 
animals were allowed to recover after surgery and kept in the an-
imal house of Hong Kong Baptist University.
 Western Blot Analysis 
 The protein expression of NR2B, TH,  p -c-Raf,  p -MEK1/2,  p -
ERK1/2 and  p -CREB in the area of the striatum and the protein 
expression of TH in the area of SN were studied. An equal amount 
of protein was loaded onto the sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE; 5% for NR2B, 10% for TH, 
 p -c-Raf,  p -MEK1/2,  p -ERK1/2 and  p -CREB) and transferred to a 
PVDF membrane (Bio-Rad) overnight at 15 V in transfer buffer 
(glycine, methanol, Tris-HCL, SDS, pH 8.3). The PVDF mem-
brane was then incubated with blocking agent containing 5% 
nonfat powdered milk (Carnation) in TBST-T (1 ! TBS, 0.1% 
Tween-20, pH 7.4) for 1 h at room temperature. After blocking, 
the membrane was incubated with anti-NR2B antibody (1: 500; 
Millipore), anti-TH antibody (1: 2,000; Millipore), anti- p -CREB
(1: 1,000; Cell Signaling), anti- p -ERK1/2 (1: 1,000; Cell Signaling), 
anti- p -MEK1/2 (1: 1,000; Cell Signaling) or anti- p -c-Raf (1: 1,000; 
Cell Signaling), which were diluted in 2% nonfat powdered milk 
(Carnation) in TBST-T (1 ! TBS, 0.1% Tween-20, pH 7.4) for 2 h 
at room temperature. Afterwards, the membrane was incubated 
with secondary horseradish peroxidase-conjugated secondary 
antibody (Zymed Laboratories) diluted in 2% nonfat powdered 
milk (Carnation) in TBST-T (1 ! TBS, 0.1% Tween-20, pH 7.4) for 
1 h at room temperature. The ECL Western blot detection re-
agents (Amersham Biosciences, England) was used for luminesc-
ing the immunoblot for detection, and the resulting light was de-
tected by BioMax film (Kodak). Immunoblots were subsequently 
stripped using the stripping buffer and sequentially reprobed 
with the loading control antibody   -actin (1: 3,000, Millipore). 
The images of the blots after Western blot analysis were digitally 
scanned by a scanner. The intensity of optical density of each band 
was semiquantified by an image analyzing software (Metamorph) 
and statistically by Duncan’s multiple range test (SPSS).
 Immunohistochemistry 
 The rats were deeply anesthetized with an overdose of sodium 
pentobarbital (60 mg/kg i.p.; Nembutal, Abbott Laboratories) be-
fore being perfused transcardially with 300 ml of 0.9% saline and 
300 ml of 3% of paraformaldehyde (Fluka) with 0.01% glutaralde-
hyde (Fluka) in phosphate buffer (0.1  M , pH 7.4) with the aid of a 
peristaltic pump. The brains were removed from the skull quick-
ly after perfusion and post-fixed in 3% paraformaldehyde (Fluka) 
overnight at 4   °   C. The brains were coronally sectioned at 70   m 
using a vibrating microtome (Vibratome 1000; Technical Prod-
ucts International Inc.). The sections were collected in phosphate-
buffered saline (PBS, 0.01  M , pH 7.4). The immunoreactivity for 
NR2B or TH in the striatum and SN was stained by antibodies 
from Millipore. The sections were incubated in anti-NR2B (1: 500; 
Millipore) or anti-TH (1: 500; Millipore) antibody diluted in PBS 
(0.01  M , pH 7.4) with 0.1% of Triton X (USB) and 2% normal goat 
serum (NBS, Vector Labs). The sections were incubated in the 
primary antibody solution overnight at room temperature. After 
incubation, the sections were incubated in fluorochrome-conju-
gated secondary antibodies (Alexa 488, Molecular Probe) diluted 
to 1: 500 PBS (0.01  M , pH 7.4) against the primary antibodies. The 
reaction was implemented at room temperature for 2 h in the dark 
and stopped by washing three times with PBS (0.01  M , pH 7.4). 
After single immunofluorescence, all the sections were mounted 
on clean slides with mounting medium (DAKO). The sections 
were observed under a laser scan confocal microscope. Digital 
images of the areas of interest were captured under the same pa-
rameters of the confocal microscope (FluoView TM FV1000, Olym-
pus) and analyzed with Metamorph software.
 Statistical Analysis 
 All results were presented as means  8 SD from a minimum 
of three independent trials. Group data were analyzed by paired t 
tests, using PASW Statistics 18 software. Significance was set as
p  ! 0.05.
 Results 
 Rotation Number after Single and Continuous 
Administration of NR2B-Specific siRNA into
Lesioned Rats 
 A single dose of 200 n M of NR2B-specific siRNA was 
injected into the striatal region of a 6-OHDA-lesioned 
rat. To investigate the effects of the NR2B-specific siRNA 
on the behaviors of the PD models, an apomorphine-in-
duced rotation test was performed on the 7th day after the 
lesion surgery and 1 or 2 days after siRNA treatment. The 
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rotation number of the PD models was recorded. The 
control model was employed by recording the rotation 
number parallel to the experimental sets without siRNA 
application. From our experiment, no significant change 
in rotation number was found in the animal model be-
tween the rotation record of before and 1 day after the 
treatment (p  1 0.05;  fig. 1 a) after the statistical analyses. 
According to the statistical analyses, there was also no 
significant change in rotation number in the animal 
model between the record of before and 2 days after the 
treatment (p  1 0.05;  fig. 1 b).
 As there was no significant improvement in behav-
ioral effect after applying single injection of NR2B-spe-
cific siRNA to the PD models, further investigation on 
the effects of the siRNA by infusing continuously into the 
animal models for 7 days was performed; 3 n M of NR2B-
specific siRNA was continuously infused into the striatal 
region of a 6-OHDA-lesioned rat for 7 days. The total 
amount of NR2B-specific siRNA infused into the rat 
models was the same as the single administration. An 
apomorphine-induced rotation test was performed on 
the 7th day after the lesion surgery and on the 7th day 
after the implantation of the siRNA-containing osmotic 
pump. The control model was employed by recording the 
rotation number parallel to the experimental set without 
siRNA application. A significant increase in rotation 
number was found in the lesioned models (p  ! 0.05; 19.57 
 8 11.69%;  fig.  1 c). However, a significant reduction of 
rotation number was found in the siRNA-treated lesioned 
model. (p  ! 0.001; 41.94  8 22.13%;  fig. 1 c).
 Protein Expression of NR2B in the Striatum 
 In order to ensure the specificity of the NR2B-specific 
siRNA, the expression of NR2A protein was also exam-
ined. The band of NR2A protein ( fig. 2 a) had a molecular 
weight between 170 and 180 kDa. The protein level of 
NR2A was not found to be reduced in both lesioned mod-
els with or without siRNA treatment. Statistical analyses 
revealed there was no significant reduction (p  1 0.05; 
 fig. 2 b). Furthermore, the silencing effect of NR2B-spe-
cific siRNA on the protein expression of NR2B in the 
models was quantitatively investigated by Western blot-
ting. The expression of NR2B protein was examined in 
total striatal protein homogenates including both the 
membrane and cytoplasmic compartments. The band of 
protein that corresponded to the NR2B protein was ob-
served with molecular weights between 170 and 180 kDa. 
After the single administration of siRNA, a significant 
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 Fig. 1. Rotation number of the 6-OHDA-lesioned parkinsonian models. In each set of experiments, control 
models were done using lesioned models without any siRNA treatment and recording the rotation number par-
allel to the tested models. The rotation number before and 1 day ( a ) or 2 days  ( b ) after the single injection of 
NR2B-specific siRNA. No significant difference was found.  c The rotation number before and after 7 days of 
continuous infusion of NR2B-specific siRNA. A significantly different reduction in rotation number was found 
in the siRNA-treated PD models. 
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reduction in protein expression of NR2B was found 
( fig. 3 a, b). The protein expression of NR2B was normal-
ized with the expression of   -actin (p  ! 0.05; 47.51  8 
15.00%;  fig. 3 c). In addition, a non-sense siRNA which 
was suggested to be minimal targeting of known genes in 
human, mouse and rat cells (Dharmacon) was used as a 
negative control in the experiment ( fig. 3 a, b). In addition, 
the protein level of NR2B in the PD models was examined 
after infusing NR2B-specific siRNA for 7 days continu-
ously. The immunoreactive band corresponding to NR2B 
protein was found to be reduced ( fig. 3 d). Statistical anal-
yses revealed there was a significant reduction (p  ! 0.01; 
57.21  8 2.27%;  fig. 3 e).
 Protein Expression of TH in the Striatum 
 To further investigate the effects of NR2B-specific 
siRNA on dopaminergic neurons, immunoreactivity for 
TH by Western blot analysis was performed. In the pres-
ent study, the expression of the TH protein was examined 
in total striatal protein homogenates including the mem-
brane and cytoplasmic compartments. The band of pro-
tein that corresponded to the TH protein was observed 
with molecular weights of about 60 kDa. No observable 
change in immunoreactivity for TH band was found after 
7 days of lesion surgery or after the single administration 
of siRNA (data not shown). In addition, the protein level 
of TH in the PD models was examined after infusing 
NR2B-specific siRNA for 7 days continuously. The im-
munoreactive band corresponding to the TH protein was 
found to be significantly reduced in the lesioned models 
14 days after lesion surgery ( fig. 4 a). Statistical analyses 
revealed there was significant reduction (p  ! 0.01; 39.17 
 8 4.04%;  fig. 4 b). After continuous infusion of NR2B-
specific siRNA, no significant reduction of TH immuno-
reactivity was found. Statistical analyses revealed there 
was no significant reduction (p  1 0.05). This revealed less 
reduction in TH protein expression in siRNA-treated PD 
models.
 The effects of NR2B-specific siRNA on the dopami-
nergic neurons were investigated by observing the change 
in immunoreactivity for TH in the immunofluorescence 
experiment. The comparison of the immunoreactivity 
for TH of each model between the nonlesioned side and 
the NR2B-specific siRNA-treated side of the same adult 
rat was made. From the results of the confocal micro-
scope, single immunofluorescence showed that the im-
munoreactivity for TH in the striatal neurons decreased 
after lesion surgery (p  ! 0.05; 19.81  8 5.39%;  fig. 5 a, b). 
On the other hand, there was less reduction of immuno-
reactivity for TH after a single injected dose of siRNA
(p  1 0.05; 2.58  8 22.42%;  fig. 5 c, d). The immunofluo-
rescence experiment was performed on the models which 
underwent continuous infusion of NR2B-specific siRNA 
for 7 days. Single immunoreactivity revealed that the stri-
atal neurons displayed a decrease in immunoreactivity 
for TH after lesion surgery (p  ! 0.001; 27.63  8 6.93%; 
 fig. 5 e, f), but no observable change was found in the im-
munoreactivity for TH after siRNA infusion (p  1 0.05; 
-6.22  8 21.0%;  fig. 5 g, h). The decrease in average gray 
value of the confocal images were measured and shown 
in the histograms ( fig. 5 i, j). Statistical analyses revealed 
there was less reduction in TH protein expression in
siRNA-treated PD models.
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 Fig. 2. Western blot analysis of the protein 
levels of NR2A in striatal neurons. The 
protein levels of   -actin were also ana-
lyzed for normalization. The normal (Nor) 
and lesioned (Les) sides of the same animal 
model were studied on the same blot.  a The 
immunoreactive band of the protein that 
corresponded to the NR2A protein which 
was observed to be about 170–180 kDa.
 b Statistical analyses revealed protein ex-
pression of NR2A in the striatum after 
normalization was not found to be re-
duced. 
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 Protein Expression of TH in the SN 
 The expression of TH protein in the SN region was re-
vealed by Western blotting. The expression of TH protein 
was examined in total protein of SN in the homogenates 
including both the membrane and cytoplasmic compart-
ments. The band of protein that corresponded to TH pro-
tein was observed with molecular weights of about 60 
kDa. The results were similar to that in the striatum, 
from which the protein expression of TH was found to 
have no observable reduction 7 days after lesion surgery 
or after the single administration of siRNA (data not 
shown). In addition, the protein level of TH in the PD 
models was examined after continuous infusion of 
NR2B-specific siRNA for 7 days. The immunoreactive 
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 Fig. 3. Western blot analysis of the protein levels of NR2B in stri-
atal neurons. The protein levels of   -actin were also analyzed for 
normalization. The normal (Nor) and lesioned (Les) sides of same 
animal model were studied on the same blot.  a Striatum (single 
injection) of normal rats. A single immunoreactive band of about 
180 kDa was observed in each of the samples. Reduction in the 
protein levels of NR2B were found in the normal models treated 
with NR2B-specific siRNA. The models treated with non-sense 
siRNA show no observable change in immunoreactive band of 
NR2B protein, which acted as a negative control of the experi-
ment.  b Striatum (continuous infusion) of 6-OHDA-lesioned rats. 
A single immunoreactive band of about 180 kDa was observed in 
each of the samples. Reduction in the protein levels of NR2B were 
found in the lesioned models treated with NR2B-specific siRNA. 
 c  Protein expression of NR2B in the striatum after normalization 
(1 day treatment). Statistical analyses revealed there was a signif-
icant reduction in NR2B-specific siRNA-treated lesioned models 
(p  ! 0.05; 47.51  8 15.00%).  d Striatum (continuous infusion) of 
6-OHDA-lesioned rats. A single immunoreactive band of about 
180 kDa was observed in the lesioned models. Reduction in the 
protein levels of NR2B were found in the lesioned models con-
tinuously infused with NR2B-specific siRNA for 7 days.  e Protein 
expression of NR2B in the striatum after normalization (1 day 
treatment). Statistical analyses revealed there was a significant 
reduction in protein expression of NR2B in the NR2B-specific 
siRNA-treated lesioned models (p  ! 0.01; 57.21  8 2.27%). 
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band corresponding to the TH protein was found to be 
significantly reduced in the lesioned models 14 days after 
lesion surgery ( fig. 4 c). Statistical analyses revealed there 
was significant reduction (p  ! 0.05; 41.91  8 5.62%; 
 fig. 4 d) in TH protein expression. However, after infusing 
NR2B-specific siRNA into the lesioned rat models con-
tinuously for 7 days, no significant reduction of TH im-
munoreactivity was found (p  1 0.05). Less reduction in 
TH protein expression was revealed in siRNA-treated PD 
models.
 Apart from Western blotting, an immunofluores-
cence experiment was also performed. The comparison 
of the immunoreactivity for TH of each model between 
the nonlesioned side and the NR2B-specific siRNA-treat-
ed side of the same adult rat was made. Similar results in 
the striatum were found. Single immunofluorescence re-
vealed that the immunoreactivity for TH in the SN neu-
rons decreased after lesion surgery ( fig. 5 k, l). Neverthe-
less, less reduction of immunoreactivity for TH after a 
single dose of siRNA injection was found ( fig. 5 m, n). In 
addition, an immunofluorescence experiment was per-
formed on the models which underwent continuous infu-
sion of NR2B-specific siRNA for 7 days. Single immuno-
reactivity revealed that the immunoreactivity for TH in 
striatal neurons decreased after lesion surgery ( fig. 5 o, p), 
but there was no observable change in the immunoreac-
tivity for TH after siRNA infusion ( fig. 5 q, r). For further 
investigation on the effects of NR2B-specific siRNA on 
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 Fig. 4. Western blot analysis of the protein levels of TH in striatal 
and SN neurons after continuous infusion of NR2B-specific
siRNA. The protein levels of   -actin were also analyzed for nor-
malization. The normal (Nor) and lesioned (Les) sides of the same 
animal model were studied on the same blot.  a Striatum (contin-
uous infusion) of 6-OHDA-lesioned rats. No observable change 
in immunoreactivity for the TH band was found in striatal neu-
rons after 7 days of lesion surgery.  b Protein expression of TH in 
the striatum of PD models after siRNA treatment (7-day treat-
ment). Statistical analyses revealed there was significant reduc-
tion of TH protein expression in striatum of the lesioned models 
(p  ! 0.01; 39.17  8 4.04%); however, no significant reduction of TH 
protein expression was found in the NR2B-specific siRNA-treat-
ed lesioned models.  c SN (continuous infusion) of 6-OHDA-le-
sioned rats. No observable change in immunoreactivity for the 
TH band was found in SN neurons after 7 days of lesion surgery. 
 d Protein expression of TH in SN of PD models after siRNA treat-
ment (7-day treatment). Statistical analyses revealed there was a 
significant reduction of TH protein expression in SN neurons of 
the lesioned models (p  ! 0.05; 41.91  8 5.62%); however, no sig-
nificant reduction of TH protein expression in SN neurons was 
found in the NR2B-specific siRNA-treated lesioned models. 
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SN neurons, cell counting was done in order to examine 
the change in number of TH-positive neurons. A com-
parison was made between the nonlesioned side and the 
lesioned side or lesioned side with siRNA treatment of the 
same adult rat. The present results show no significant 
difference in the number of TH-positive neurons in both 
lesioned-only and siRNA-treated PD models in the single 
injection group ( fig. 5 s). However, a significant reduction 
in number of TH-positive neurons was found in lesioned-
only PD models in the continuous infusion group (54.17 
 8 6.12%;  fig.  5 t), while no significant difference was 
found in the siRNA-treated PD models.
 Protein Expression of ERK Signaling Effectors 
 Western blot analysis was employed and several effec-
tors in the ERK signaling pathway were investigated in 
both normal and lesioned animal models, which includ-
ed  p -c-Raf,  p -MEK  p -ERK1/2 (Thr202/Tyr204) and  p -
CREB. From the results, no observable change in protein 
level of any investigated effector was found in the normal 
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 Fig. 5. Immunofluorescence experiment was performed in stria-
tal and SN neurons.  a ,  b Single immunofluorescence revealed that 
the striatal neurons displayed a decrease in the immunoreactivity 
for TH after lesion.  c ,  d Less reduction of immunoreactivity for 
TH after a single dose of siRNA injection was found.  e ,  f Single 
immunoreactivity revealed that the striatal neurons displayed a 
decrease in immunoreactivity for TH after lesion.  g ,  h No observ-
able change in the immunoreactivity for TH after siRNA infu-
sion.  i ,  j Average gray value of the striatum of PD models after 
siRNA treatment. Statistical analyses revealed there was a signif-
icant reduction of TH protein expression in the striatum of the 
lesioned models (single injection group; p  ! 0.05; 19.81  8 5.39%; 
continuous infusion group; p  ! 0.001; 27.63  8 6.93%). However, 
no reduction in immunoreactivity for TH was found in either 
single administration or continuous infusion of NR2B-specific 
siRNA-treated PD models.  k ,  l Single immunofluorescence re-
vealed that the SN neurons displayed a decrease in the immuno-
reactivity for TH after lesion.  l ,  m Less reduction of immunoreac-
tivity for TH after a single dose of siRNA injection was found.
 o ,  p Single immunoreactivity revealed that the SN neurons dis-
played a decrease in immunoreactivity for TH after lesion.  q ,  r No 
observable change in the immunoreactivity of TH after siRNA 
infusion.  s ,  t Number of TH-positive cells in SN of lesioned mod-
els after siRNA treatment. Cell counting was employed and the 
change in the number of TH-positive neurons after treatment was 
examined. Statistical analyses revealed there was a significant re-
duction of TH-positive neurons in SN neurons of the lesioned 
models (continuous infusion group; p  ! 0.001; 54.17  8 6.12%). 
However, no reduction in the number of TH-positive neurons was 
found in either single administration or continuous infusion of 
NR2B-specific siRNA-treated PD models. 
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rat models. In the lesioned rat models, no significant dif-
ference in the protein expression of  p -c-Raf was observed 
after continuous infusion of NR2B-specific siRNA into 
6-OHDA lesioned rat models ( fig. 6 a).  p -MEK, which is 
activated by MAP kinase kinase kinase (MAP3K) c-Raf, 
also showed no significant difference in the protein ex-
pression after continuous infusion of NR2B-specific
siRNA into 6-OHDA-lesioned rat models ( fig. 6 b). In ad-
dition, the results from Western blot analysis on the stri-
atum of NR2B-specific siRNA-treated 6-OHDA-lesioned 
rat models revealed a significant increase (p  ! 0.05; 86.29 
 8 62.69%;  fig. 6 c) in the protein expression of  p -ERK1/2 
(Thr202/Tyr204). Western blot analysis was also em-
ployed on the SN of NR2B-specific siRNA-treated 6-
OHDA-lesioned rat models. However, the results showed 
a significant reduction (p  ! 0.05; 32.04  8 11.80%;  fig. 6 e) 
in the protein levels of  p -ERK1/2 (Thr202/Tyr204) in the 
siRNA-treated 6-OHDA-lesioned rat models. The change 
of protein expression of  p -CREB which could be activat-
ed by the ERK signaling pathway was investigated in the 
present study. The results showed a significant upregula-
tion (p  ! 0.05; 144.26  8 105.63%;  fig. 6 d) in the protein 
expression of  p -CREB after continuous infusion of 
NR2B-specific siRNA into 6-OHDA-lesioned rat models. 
Statistical analyses of different phosphorylated form of 
effectors in striatal and SN neurons after continuous in-
fusion of NR2B-specific siRNA were done and are showed 
in a histogram ( fig. 7 a–e).
 Discussion 
 The results of the present study indicate that applica-
tion of NR2B-specific siRNA can potentially conduce the 
amelioration of motor behavior and reservation of the 
dopaminergic neurons of PD animal models, especially 
in the continuous infusion models. Moreover, NR2B-
specific siRNA can promote the survival signaling path-
way by upregulating the protein levels of  p -ERK1/2 and 
 p -CREB. These observations may form a basis for apply-
ing gene silencing targeting NR2B as a potent treatment 
of PD.
 Change in Rotation Number after Administration of 
NR2B-Specific siRNA into Lesioned Rats 
 The alternations in dopamine receptors in 6-OHDA-
treated animal models lead to glutamatergic overstimula-
tion in the indirect striatal output pathway which eventu-
ally causes the PD motor symptoms  [5, 7] . Moreover, the 
imbalance in dopamine activity  [35, 36] will lead the an-
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e
 Fig. 6. Western blotting analysis of the protein levels of different 
phosphorylated forms of effectors in striatal and SN neurons after 
continuous infusion of NR2B-specific siRNA. The protein levels 
of the nonphosphorylated form of each effector were also ana-
lyzed for normalization. The normal (Nor) and lesioned (Les) 
sides of the same animal model were studied simultaneously.  a No 
observable change in the immunoreactivity band for  p -c-Raf was 
found in striatal neurons.  b No observable change in the immu-
noreactivity band for  p -MEK was found in striatal neurons.  c A 
significant upregulation in immunoreactivity band for  p -ERK1/2 
was found in striatal neurons.  d A significant upregulation in the 
immunoreactivity band for  p -CREB was found in striatal neu-
rons.  e A significant downregulation in the immunoreactivity 
band for  p -ERK1/2 was found in SN neurons. 
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imals to respond to dopamine agonists such as apomor-
phine by contralateral rotation to the lesioned side  [36–
38] . In the present study, the number of rotations between 
the lesioned models and lesioned-with-siRNA-treatment 
models were compared. It is shown that a significant 
modification of motor behavior in the rat rotation test 
after the treatment of 7 days continuous infusion of 
NR2B-specific siRNA. As the total administration 
amount of NR2B-specific siRNA (7.8 ng) used was the 
same in both the single injection and the continuous in-
fusion models, the differences between the two sets of 
experiments may be related to the duration of the applica-
tion of siRNA into the striatal region. After the adminis-
tration of NR2B-specific siRNA into striatum, expres-
sion of functional NMDAR may be reduced. Moreover, 
the overstimulated glutamatergic activity of striatal neu-
rons may also be reduced, which can further diminish the 
stimulation on the overactivated subthalamic nucleus 
and reduce the inhibition on the output nuclei of the bas-
al ganglia and hence reduce the motor symptoms of PD. 
The present results indicated that the NR2B-specific siR-
NA is capable of ameliorating the motor symptoms in 
parkinsonian models.
 Downregulation of NR2B in the Lesioned Side of 
siRNA-Treated Lesioned Rats 
 Overstimulation of NR2B-containing NMDAR in the 
striatum was reported to contribute to the generation of 
parkinsonian symptoms  [39–42] . The finding in the 
present study indicated an increasing trend of protein ex-
pression of NR2B in the striatum after the lesion surgery, 
which was in agreement with the previous study  [38, 43–
45] . Furthermore, reduction in NR2B protein expression 
was found in both the single-dose administration and 
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 Fig. 7. Statistical analyses of different phosphorylated forms of ef-
fectors in striatal and SN neurons after continuous infusion of 
NR2B-specific siRNA.  p -c-Raf ( a ) and  p -MEK1/2 ( b ) protein ex-
pression in the striatum after normalization. Statistical analyses 
revealed there was no significant change of  p -c-Raf and  p -MEK 
protein expression in the striatum of NR2B-specific siRNA-treat-
ed lesioned models.  c  p -Erk1/2 protein expression in the striatum 
after normalization. Statistical analyses revealed there was sig-
nificant upregulation of  p -ERK1/2 protein expression in the stri-
atum of NR2B-specific siRNA-treated lesioned models (p  ! 0.05; 
86.29  8 62.69%).  d  p -Erk1/2 protein expression in the SN after 
normalization. Statistical analyses revealed there was significant 
downregulation of  p -ERK1/2 protein expression in the SN of 
NR2B-specific siRNA-treated lesioned models (p  ! 0.05; 32.04 
 8 11.80%).  e  p -CREB protein expression in the striatum after nor-
malization. Statistical analyses revealed there was significant up-
regulation of  p -CREB protein expression in the striatum of 
NR2B-specific siRNA-treated lesioned models (p  ! 0.05; 144.26 
 8 105.63%). 
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continuous infusion of NR2B-specific siRNA-treated 
parkinsonian models. By comparing the results between 
the siRNA treatment by continuous infusion (p  ! 0.01; 
57.21%) and siRNA treatment by single-dose administra-
tion (p  ! 0.05; 47.51%), a more significant reduction in 
NR2B protein expression was found in the striatal region 
of the infusion models, which indicates continuous infu-
sion is the more efficient application method.
 The NMDAR subunits NR2A and NR2B have been 
reported to be the major subtypes of NMDAR colocalized 
in the striatum  [7, 46] , and shared considerable homolo-
gy – up to 70% identical  [7, 47] . No observable reduction 
in immunoreactivity for NR2A was found in Western 
blot analysis, indicating that the siRNA used in the ex-
periment was specific to NR2B mRNA in the striatum. 
Moreover, a nontargeting siRNA, which was suggested to 
minimally target known genes in human, mouse and rat 
cells was purchased from a commercial company (Dhar-
macon) and acted as a negative control for the experi-
ment. These results also indicated that NR2B-specific 
siRNA used in the present experiments is an effective 
agent and specific in blocking the protein expression of 
the NR2B subunit.
 NR2B-Specific siRNA Protect TH-Immunoreactive 
Dopamine Neurons against 6-OHDA Toxicity 
 Loss of TH immunoreactivity can reveal the loss of the 
TH-positive neurons, dopaminergic neurons. Previous 
studies demonstrated that NR2B antagonists exhibited 
neuroprotective effects  [41, 42, 48, 49] . In the present 
study, reduction in TH immunoreactivity was found in 
the striatum and SN after 6-OHDA was lesioned. By 
comparing the TH immunoreactivity of lesioned models 
and siRNA-lesioned treatment models, a 19.8 or 27.6% 
significant decrease in TH immunoreactivity was found 
in the PD models 7 or 14 days after lesion surgery, respec-
tively, while only a 5.39% decrease or 6.21% increase was 
found after single or continuous siRNA treatment. These 
results implicated that dopaminergic cell loss was signif-
icantly attenuated and the neuroprotective effect may be 
mediated by NR2B-specific siRNA. The present results 
suggest that reduction of the subunit of NMDAR may 
lead to the decrease of the functional NR2B-containing 
NMDAR present on the striatum, which may increase the 
inhibition signal in the indirect pathway. Hence, the 
overactivation of the glutamatergic activity of the subtha-
lamic nucleus is restored and cell death due to the over-
stimulation of the NMDAR localized on the dopaminer-
gic neurons is prevented. However, this phenomenon was 
only observed in the models that underwent continuous 
infusion of NR2B-specific siRNA. As the total amount of 
siRNA introduced to the parkinsonian models by the two 
methods was the same, the effect of siRNA should be re-
lated to the duration of the application. In addition, the 
amount of dopaminergic cell loss was suggested in a pre-
vious study, which correlates with behavioral deficit in 
6-OHDA-lesioned animal models  [42, 50] . In the present 
study, it can also be concluded that the significant im-
provement in the behavior in 6-OHDA-lesioned rats with 
continuous infusion of NR2B-specific treatment may be 
due to the attenuation of dopaminergic cell loss in the 
striatum and SN.
 Change in p-ERK1/2 and Upregulation of p-CREB 
Protein Expression in the Lesioned Side of
siRNA-Treated Lesioned Rats 
 In the present study, the ERK1/2 prosurvival cascade 
was hypothesized to be consistent in the neuroprotective 
phenomenon. The significant upregulation of  p -ERK1/2 
protein after administration of NR2B-specific siRNA re-
vealed that activation of the ERK1/2 signaling pathway 
occurred. NR2B-containing NMDAR expressed in ex-
trasynaptic NMDAR was reported to trigger a signaling 
cascade leading to inactivation of the ERK1/2 signaling 
pathway  [26] . Reducing the expression of extrasynaptic 
NR2B-containing receptors probably results in releasing 
the inhibition of ERK1/2 activity, i.e. increasing the phos-
phorylation of ERK1/2. As mentioned earlier, synaptic 
NMDAR was predominantly composed of NR2A-con-
taining NMDARs  [25] , which was independent of the si-
lencing effect of NR2B-specific siRNA. Thus, activation 
of synaptic NR2A-containing NMDARs probably occurs 
and the influx of Ca 2+ may result in triggering the phos-
phorylation of ERK1/2 which may contribute to the sig-
nificant increase in  p -ERK1/2 protein in striatal neurons. 
Moreover, a significant upregulation of  p -CREB in 
NR2B-specific siRNA-treated 6-OHDA-lesioned rats 
was found in the present study. It is probably related to 
the activation of the ERK1/2 cascade pathway which was 
reported to be the exclusively Ca 2+ -dependent signal 
transduction pathways that mediated CREB phosphory-
lation  [51] . As CREB is a transcription factor that is well 
known to be the key element in the neuronal survival 
pathway  [52] , Ser133  p -CREB carries out prosurvival ac-
tivities by controlling the transcription of numerous neu-
roprotective genes  [23, 52–54] .
 However, a significant reduction of  p -ERK1/2 protein 
was found in SN neurons. As NR2B-specific siRNA was 
applied to the striatal region, the neuroprotective effect 
by reducing the activity of NMDAR NR2B subunits was 
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